Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer.
Prostate cancer is the most common noncutaneous cancer among men. This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that responded initially to docetaxel and did not tolerate cabazitaxel. He subsequently received a third line of chemotherapy with cyclophosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.
From Department of Medicine, Roswell Park Cancer Center, Buffalo, New York.
Nicolas
N
Batty
Naveen
N
Yarlagadda
Roberto
R
Pili
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D043823:Taxoids; D000077143:Docetaxel; C552428:cabazitaxel; D003520:Cyclophosphamide; D017430:Prostate-Specific Antigen; D011241:Prednisone